BACKGROUND: Monitoring blood levels of human growth hormone (hGH) in most children with short stature deficiencies is crucial for taking a decision of treatment with extended course of daily and expensive doses of recombinant hGH (rhGH or Somatropin®). Besides, misusing of rhGH by sportsmen is banned by the World Anti-Doping Agency and thus sensitive GH-detecting methods are highly welcome in this field. Nanobodies are the tiniest antigen-binding entity derived from camel heavy chain antibodies. They were successfully generated against numerous antigens including hormones. METHODS: A fully nanobody-based sandwich ELISA method was developed in this work for direct measurement of GH in biological samples. RESULTS: Two major characteristics of nanobody were exploited for this goal: the robust and stable structure of the nanobody (NbGH04) used to capture hGH from tested samples, and the great ability of tailoring, enabling the display of the anti-GH detector nanobody (NbGH07) on the tip of M13-phage. Such huge, stable, and easy-to-prepare phage-Nb was used in ELISA to provide an amplified signal. Previously, NbGH04 was retrieved on immobilized hGH by phage display from a wide "immune" cDNA library prepared from a hGH-immunized camel. Here, and in order to assure epitope heterogeneity, NbGH07 was isolated from the same library using NbGH04-captured hGH as bait. Interaction of both nanobodies with hGH was characterized and compared with different anti-GH nanobodies and antibodies. The sensitivity (~0.5 ng/ml) and stability of the nanobody-base sandwich ELISA were assessed using rhGH before testing in the quantification of hGH in blood sera and cell culture supernatants. CONCLUSION: In regard to all advantages of nanobodies; stability, solubility, production affordability in Escherichia coli, and gene tailoring, nanobody-based phage sandwich ELISA developed here would provide a valuable method for hGH detection and quantification.
BACKGROUND: Monitoring blood levels of humangrowth hormone (hGH) in most children with short stature deficiencies is crucial for taking a decision of treatment with extended course of daily and expensive doses of recombinant hGH (rhGH or Somatropin®). Besides, misusing of rhGH by sportsmen is banned by the World Anti-Doping Agency and thus sensitive GH-detecting methods are highly welcome in this field. Nanobodies are the tiniest antigen-binding entity derived from camel heavy chain antibodies. They were successfully generated against numerous antigens including hormones. METHODS: A fully nanobody-based sandwich ELISA method was developed in this work for direct measurement of GH in biological samples. RESULTS: Two major characteristics of nanobody were exploited for this goal: the robust and stable structure of the nanobody (NbGH04) used to capture hGH from tested samples, and the great ability of tailoring, enabling the display of the anti-GH detector nanobody (NbGH07) on the tip of M13-phage. Such huge, stable, and easy-to-prepare phage-Nb was used in ELISA to provide an amplified signal. Previously, NbGH04 was retrieved on immobilized hGH by phage display from a wide "immune" cDNA library prepared from a hGH-immunized camel. Here, and in order to assure epitope heterogeneity, NbGH07 was isolated from the same library using NbGH04-captured hGH as bait. Interaction of both nanobodies with hGH was characterized and compared with different anti-GH nanobodies and antibodies. The sensitivity (~0.5 ng/ml) and stability of the nanobody-base sandwich ELISA were assessed using rhGH before testing in the quantification of hGH in blood sera and cell culture supernatants. CONCLUSION: In regard to all advantages of nanobodies; stability, solubility, production affordability in Escherichia coli, and gene tailoring, nanobody-based phage sandwich ELISA developed here would provide a valuable method for hGH detection and quantification.
Authors: G De Lorenzo; C Eichwald; E M Schraner; V Nicolin; R Bortul; M Mano; O R Burrone; F Arnoldi Journal: J Gen Virol Date: 2012-03-21 Impact factor: 3.891
Authors: K E Conrath; M Lauwereys; M Galleni; A Matagne; J M Frère; J Kinne; L Wyns; S Muyldermans Journal: Antimicrob Agents Chemother Date: 2001-10 Impact factor: 5.191
Authors: Mohamed El Khattabi; Hendrik Adams; Erik Heezius; Pim Hermans; Frank Detmers; Bram Maassen; Peter van der Ley; Jan Tommassen; Theo Verrips; Jord Stam Journal: Clin Vaccine Immunol Date: 2006-08-23
Authors: Rob C Roovers; Maria J W D Vosjan; Toon Laeremans; Rachid el Khoulati; Renée C G de Bruin; Kathryn M Ferguson; Arie J Verkleij; Guus A M S van Dongen; Paul M P van Bergen en Henegouwen Journal: Int J Cancer Date: 2011-08-08 Impact factor: 7.396
Authors: Luciano J Melli; Vanesa Zylberman; Yanina Hiriart; Constanza E Lauche; Ariela Baschkier; Romina Pardo; Elizabeth Miliwebsky; Isabel Chinen; Marta Rivas; Fernando A Goldbaum; Juan E Ugalde; Diego J Comerci; Andrés E Ciocchini Journal: J Clin Microbiol Date: 2020-02-24 Impact factor: 5.948